Background: Infectious diseases remain a significant cause of morbidity and mortality. Cefpirome, a fourth generation Cephalosporin, is a potent antibiotic against a wide variety of organisms that may be used alone or in combination with other antimicrobials to combat various infections.

Objective: This is a post-marketing surveillance study documenting the safety and efficacy of cefpirome among Filipino patients.

Methodology: This was a multicenter, open-label, non-comparative study involving 402 patients who received at least one dose of cefpirome. Safety and efficacy data were gathered.

Results: Cefpirome was used as monotherapy in majority of the cases. Pneumonia (76%) was the most frequent indication for the use of this drug. The most commonly utilized dosage regimen was 2.0 grams every 12 hours for a mean of 4.2 days. This was associated with a successful clinical outcome in almost 90% of cases. There was almost negligible side effect reported.

Conclusion: The use of cefpirome was shown to be safe and well-tolerated with associated successful clinical outcomes among Filipino patients.

Keywords: cefpirome, efficacy, Filipino

1. Caballero J, Rello J. Combination Antibiotic therapy for Community-Acquired Pneumonia.Annals of Intensive Care.1:48-53, 2011.
2. Wolff M. et al. Comparison of strategies using Cefpirome and Ceftazidime for empiric treatment of Pneumonia in intensive care units.Antimicrobial Agents and Chemotherapy.p28-36, 1998.
3. Yu-Chieh Su et al. An observational study on the empiric use of cefpirome in febrile neutropenia.Journal of Microbiology, Immunology and Infection. 40:62-67, 2007.
4. Dellinger RP.et al. Surviving Sepsis Campaign: International Guidelines for the Management of Sever Sepsis and Septic Shock: 2012. Critical Care Medicine.41(2): 580-637, 2013 February.
5. Lindenmann J et al. High extracellular levels of Cefpirome in unaffected and infected lung tissue of patients.Journal of Antimicrobial Chemotherapy. 66(1): 160-164, 2011.
6. Jain A. Sing K. Recent advances in the management of nosocomial infections.Journal of Medical Education and Research(JK Sciences). 9(1):3-8; 2007.
7. Norby S. et al. Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteremia or sepsis.Journal of Antimicrobial and Chemotherapy. 42: 503-509, 1998.
8. Philippine Clinical Practice Guidelines on the Diagnosis, Empiric Management and Prevention of Community Acquired PneumoniainImmunocompetent Adults 2010 Update.
9. American Thoracic Society and Infectious Disease Society of America. Guidelines for the management of Adults with Hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.American Journal of Respiratory and Critical Care Medicine. 171:388-416, 2005.
10. King PT and Holmes PW. Use of antibiotics in Bronchiectasis.Reviews on Recent Clinical Trials. 7(1): 24-30, 2012 February.
11. Jacolot A. et al. Pharmacokinetics of Cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Medicine. 25:486-491, 1999
12. Lipman J. et al. Low cefpirome levels during twice daily dosing in critically ill septic patients: Pharmacokinetic modeling calls for more frequent dosing. Intensive Care Medicine. 27:363-370, 2001.
13. Joukhadar C. et al. Plasma and tissue pharmacokinetics of Cefpirome in patients with sepsis.Critic Care Medicine. 30(7): 1478-1482, 2002.
14. Sauermann R. et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.Antimicrobial Agents and Chemotherapy. 49(2):650- 655, 2005.
15. Roos J. et al. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-Negative bacteria.Intensive Care Medicine. 33:781-788, 2007.